A Philadelphia jury has awarded $1.75 million to a plaintiff who alleged that taking the antipsychotic drug Risperdal caused gynecomastia, a condition in which boys grow excessive breast tissue.
The jury handed up the verdict in Murray v. Janssen Pharmaceuticals on Monday following about two weeks of trial and two-and-a-half hours of deliberations. The jury determined that Janssen Pharmaceuticals, which made the drug, failed to warn health care providers about gynecomastia as a risk of taking the drug, and the failure to warn caused plaintiff Nicholas Murray’s injuries.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
